Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44,112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
Chen Z, Huang H, Huang H, Yu L, Weng H, Xiao J, Zou L, Zhang H, Liang C, Zhou H, Guo H, Wang Z, Li Z, Wu T, Zhang H, Wu H, Peng Z, Zhai L, Chen X, Liang Y, Hong H, Lin T. Chen Z, et al. Among authors: wu h, wu t. Leukemia. 2024 Apr;38(4):829-839. doi: 10.1038/s41375-024-02171-4. Epub 2024 Feb 20. Leukemia. 2024. PMID: 38378844
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.
Wang T, Sun X, Qiu L, Su H, Cao J, Li Z, Song Y, Zhang L, Li D, Wu H, Zhang W, Li J, Zhou K, Zhou H, Yang Y, Li Z, Cen H, Cai Z, Zhang Z, Fu W, Jin J, Li F, Wu W, Gu X, Zhu W, Liu L, Li Z, Yi S, Bao H, Xu Z, Qiu L. Wang T, et al. Among authors: wu h, wu w. Clin Cancer Res. 2023 Apr 14;29(8):1440-1449. doi: 10.1158/1078-0432.CCR-22-2939. Clin Cancer Res. 2023. PMID: 36735519 Free PMC article. Clinical Trial.
Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2.
Wang J, Shao L, Liang J, Wu Q, Zhu B, Deng Q, Liu Z, Liu L, Wang D, Yu Z, Tan X, Wang F, Meng J, Xu X, Xia Z, Li Z, Wang H, Wang L, Wu W, Xie Q, Huang X, Sun Z, Zhang Y, Zhou H, Zhou H, Yang W, Ren H, Liu Z, Qiao M, Tang F, Qi X, Wu H, Deng L, Gao L, Zhang H, Chen P, Zhang H, Zhang X, Zhou J, Chuanqing TU, Guan L, Yin Q, Shu R, Chen F, He M, Wang Q, Guo Z; Tumor and Microecology Committee of China Anti-Cancer Association; Chinese Collaborative Group on Transformation of Infectious Immunology and Microecology Research. Wang J, et al. Among authors: wu h, wu w, wu q. J Cancer Res Ther. 2023 Dec 1;19(6):1495-1500. doi: 10.4103/jcrt.JCRT_782_23. Epub 2023 Dec 28. J Cancer Res Ther. 2023. PMID: 38156914 Free article.
Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma.
Wang H, Feng J, Liu Y, Qian Z, Gao D, Ran X, Zhou H, Liu L, Wang B, Fang M, Zhou H, Huang Z, Tao S, Chen Z, Su L, Su H, Yang Y, Xie X, Wu H, Sun P, Hu G, Liang A, Li Z. Wang H, et al. Among authors: wu h. Signal Transduct Target Ther. 2024 Apr 17;9(1):99. doi: 10.1038/s41392-024-01798-0. Signal Transduct Target Ther. 2024. PMID: 38627366 Free PMC article. Clinical Trial.
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
Gao Y, He H, Li X, Zhang L, Xu W, Feng R, Li W, Xiao Y, Liu X, Chen Y, Wang X, Bai B, Wu H, Cai Q, Li Z, Li J, Lin S, He Y, Ping L, Huang C, Mao J, Chen X, Zhao B, Huang H. Gao Y, et al. Among authors: wu h. Signal Transduct Target Ther. 2024 May 17;9(1):121. doi: 10.1038/s41392-024-01825-0. Signal Transduct Target Ther. 2024. PMID: 38755119 Free PMC article. Clinical Trial.
44,112 results
You have reached the last available page of results. Please see the User Guide for more information.